Therapy Detail

Therapy Name TVB-2640
Therapy Description

TVB-2640 is a fatty acid synthase (FASN) inhibitor that inhibits lipid metabolism in tumor cells (PMID: 26519059).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
TVB-2640 TVB2640 FASN Inhibitor 5 TVB-2640 is a fatty acid synthase (FASN) inhibitor that inhibits lipid metabolism in tumor cells (PMID: 26519059).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown non-small cell lung carcinoma not applicable TVB-2640 Phase I Actionable In a Phase I study, TVB-2640 as a monotherapy or in combination with Taxol (paclitaxel) resulted in stable diseases for more than 16 weeks in 43% (3/7) of patients with non-small cell lung cancer (2015 51 S724-S724 Eur J Cancer). detail...
Unknown unknown Advanced Solid Tumor not applicable TVB-2640 Phase I Actionable In a Phase I trial, TVB-2640 demonstrated bioavailability and inhibited FASN-dependent signaling in the tumor tissue of one patient with advanced solid tumor (Cancer Res August 1, 2015 75; 2675). detail...
KRAS mutant non-small cell lung carcinoma predicted - sensitive TVB-2640 Phase I Actionable In a Phase I trial, TVB-2640 treatment resulted in stable disease for more than 17 weeks in 100% (3/3) of patients with non-small cell lung carcinoma harboring KRAS mutations (J Clin Oncol 34, 2016 (suppl; abstr 2512)). detail...
Unknown unknown triple-receptor negative breast cancer not applicable TVB-2640 Phase I Actionable In a Phase I clinical trial, TVB-2640 treatment resulted in stable disease for 20 weeks in one patient with triple-receptor negative breast cancer (2015 51 S724-S724 Eur J Cancer). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02223247 Phase I TVB-2640 A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors Completed
NCT02980029 Phase I TVB-2640 Pharmacodynamic Effects of Fatty Acid Synthase (FASN) Inhibition With TVB-2640 in Resectable Colon Cancer Recruiting
NCT03808558 Phase II TVB-2640 Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas Not yet recruiting